Literature DB >> 10861076

CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.

H Xu1, A N Hodder, H Yan, P E Crewther, R F Anders, M F Good.   

Abstract

Apical membrane Ag 1 (AMA1) is a leading malaria vaccine candidate. Homologues of AMA1 can induce protection in mice and monkeys, but the mechanism of immunity is not understood. Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami. Here we show that CD4+ T cell depletion, but not gammadelta T cell depletion, can cause a significant drop in antiparasite immunity in either immunized normal or immunized B cell KO mice. In normal mice, this loss of immunity is not accompanied by a decline in Ab levels. These observations indicate a role for AMA1-specific Ab-independent T cell-mediated immunity. However, the loss of immunity in normal CD4+ T cell-depleted mice is temporary. Furthermore, immunized B cell KO mice cannot survive infection, demonstrating the absolute importance of B cells, and presumably Ab, in AMA1-induced immunity. CD4+ T cells specific for a cryptic conserved epitope on AMA1 can adoptively transfer protection to athymic (nu/nu) mice, the level of which is enhanced by cotransfer of rabbit anti-AMA1-specific antisera. Recipients of rabbit antisera alone do not survive. Some protected recipients of T cells plus antisera do not develop their own AMA 1-specific Ab response, suggesting that AMA 1-specific CMI alone can protect mice. These data are the first to demonstrate the specificity of any protective CMI response in malaria and have important implications for developing a malaria vaccine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861076     DOI: 10.4049/jimmunol.165.1.389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria.

Authors:  Morris O Makobongo; George Riding; Huji Xu; Chakrit Hirunpetcharat; Dianne Keough; John de Jersey; Peter Willadsen; Michael F Good
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-19       Impact factor: 11.205

2.  Induction of parasite growth-inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1.

Authors:  Markus S Mueller; Annabelle Renard; Francesca Boato; Denise Vogel; Martin Naegeli; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

3.  Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.

Authors:  Sophie Schussek; Angela Trieu; Simon H Apte; John Sidney; Alessandro Sette; Denise L Doolan
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

4.  In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Authors:  Michael C Kennedy; Jin Wang; Yanling Zhang; Aaron P Miles; Farideh Chitsaz; Allan Saul; Carole A Long; Louis H Miller; Anthony W Stowers
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

5.  Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria.

Authors:  Anthony W Stowers; Michael C Kennedy; Brian P Keegan; Allan Saul; Carole A Long; Louis H Miller
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Plasmodium falciparum apical membrane antigen 1 vaccine elicits multifunctional CD4 cytokine-producing and memory T cells.

Authors:  Maria Cecilia Huaman; Gregory E D Mullen; Carole A Long; Siddhartha Mahanty
Journal:  Vaccine       Date:  2009-07-08       Impact factor: 3.641

7.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.

Authors:  Kirsten E Lyke; Modibo Daou; Issa Diarra; Abdoulaye Kone; Bourema Kouriba; Mohamadou A Thera; Sheetij Dutta; David E Lanar; D Gray Heppner; Ogobara K Doumbo; Christopher V Plowe; Marcelo B Sztein
Journal:  Vaccine       Date:  2009-01-31       Impact factor: 3.641

9.  Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors.

Authors:  A Rainczuk; T Scorza; P M Smooker; T W Spithill
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Malaria protection in beta 2-microglobulin-deficient mice lacking major histocompatibility complex class I antigens: essential role of innate immunity, including gammadelta T cells.

Authors:  Tomoyo Taniguchi; Saoko Tachikawa; Yasuhiro Kanda; Toshihiko Kawamura; Chikako Tomiyama-Miyaji; Changchun Li; Hisami Watanabe; Hiroho Sekikawa; Toru Abo
Journal:  Immunology       Date:  2007-10-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.